Telix Pharmaceuticals Securing FDA Nod in Line With Expectations, Says Jefferies, Shares Down 3%
MT Newswires Live
Jul 03
Telix Pharmaceuticals (ASX:TLX) reaching alignment with the US Food and Drug Administration (FDA) to advance a phase 3 trial of its TLX591-Tx therapeutic candidate is in line with expectations, according to a Thursday Jefferies note.
The company said on Thursday that the US regulator confirmed that safety data from part one of the study is adequate to allow for the progression of part two.
Jefferies added that the update results in no changes to forecasts or the price target for Telix Pharmaceuticals.
Jefferies kept a buy rating on Telix with a price target of AU$27.40.
The company's shares fell 3% in recent Friday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.